The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1277

Sorry, thought you were pulin' the p*ss. You say apathy, I say business as usual without the fluff. Sure, they could have made more of a song and dance about the new CEO, but do they really need to? Probably not, but I understand why others expect more. That was one move that made me wonder if there wasn't really any need to promote because it's only a role until a buyout following ODD.

The other aspect was MT's actual resignation. He seems to have met all his KPIs rewarding him with options, so there's nothing else on the table for him at this stage other than his salary (I will qualify that I am unsure about the 500k options he was due to earn on 1 Sep - maybe he still gets those?). Also, MT will have at least 2.4m in performance rights and he is still with PAA for at least 3 more months serving notice. So he's not exactly cutting and running and will be interested in the SP too.

I see silence on the Ph2/3 funding as representative of it all being in hand. Either we can expect some of the BoD to convert options to fund, or what I actually think - they have a deal lined conditional on ODD which they will walk into. If for any reason ODD was to fall over in the interim, Plan B would be option conversion.

So to me, I am wondering if we're seeing a relaxed PAA because the fat lady is approaching the stage.